secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001628280-26-001905
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River: Q4 DSA book-to-bill ~1.1x; acquires K.F. (Cambodia) for $510M and PathoQuest for ~$60M
--------------------------------------------------------------------------------

- Preliminary Q4 DSA net book-to-bill ~1.1x, driven by improved demand from small/mid biotech and global biopharma in Q4.
- 2026 organic revenue guidance expects at least flat growth for consolidated and DSA, with revenue growth returning in H2 2026.
- Non-GAAP operating margin outlook includes >$100M in incremental cost savings to offset inflation until revenue growth resumes.
- Acquiring K.F. (Cambodia) for ~$510M; accretive $0.25 in 2026, $0.60 in 2027; close expected early Q1 2026.
- Exercising option to buy remaining 79% of PathoQuest for ~€51.6M (~$60M); close by end Q1 2026, not material to 2026/2027 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000162828026001905/0001628280-26-001905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000162828026001905/crl-20260113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer